- Ciències Mèdiques Bàsiques
Departament
Josep Maria
Llovet Bayer
Publicacións nas que colabora con Josep Maria Llovet Bayer (13)
2023
-
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy
Gut, Vol. 73, Núm. 3, pp. 496-508
2022
-
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies
Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3443-3451
2021
-
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
Gastroenterology, Vol. 161, Núm. 3, pp. 879-898
2020
-
Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma
Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6350-6361
-
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Journal of Hepatology, Vol. 73, Núm. 2, pp. 315-327
2019
-
Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials
British Journal of Cancer, Vol. 121, Núm. 4, pp. 340-343
-
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Gut, Vol. 68, Núm. 6, pp. 1065-1075
-
New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma
Clinical Liver Disease, Vol. 14, Núm. 2, pp. 56-61
-
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Journal of Hepatology, Vol. 70, Núm. 6, pp. 1262-1277
2018
-
Molecular therapies and precision medicine for hepatocellular carcinoma
Nature Reviews Clinical Oncology, Vol. 15, Núm. 10, pp. 599-616
2017
-
Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity
Journal of Hepatology, Vol. 66, Núm. 5, pp. 952-961
-
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Journal of Hepatology, Vol. 66, Núm. 6, pp. 1166-1172
-
Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”
Journal of Hepatology